Aurinia Pharmaceuticals to Present at the Leerink Partners Roundtable Series in New York September 28,
2016
Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH /TSX:AUP), a clinical stage biopharmaceutical company focused on the global
immunology market, today announced that its Chief Executive Officer, Charles Rowland, will participate in a Fireside Chat at the
Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 11:05am ET in New York. To access the
live webcast, please visit the investor section of the Aurinia website. A replay will also be archived on the site following the
event.
About Aurinia
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted
patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing
voclosporin, an investigational drug, for the treatment of lupus nephritis (LN). The company is headquartered in Victoria, BC and
focuses its development efforts globally. www.auriniapharma.com
About Voclosporin
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data
in over 2,000 patients in other indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action
that has the potential to improve near- and long-term outcomes in LN when added to standard of care (MMF). By inhibiting
calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses. It is made by a modification of a single
amino acid of the cyclosporine molecule which has shown a more predictable pharmacokinetic and pharmacodynamic relationship, an
increase in potency, an altered metabolic profile, and potential for flat dosing. The Company anticipates that upon regulatory
approval, patent protection for voclosporin will be extended in the United States and certain other major markets, including Europe
and Japan, until at least October 2027 under the Hatch-Waxman Act and comparable laws in other countries.
About Lupus Nephritis (LN)
Lupus Nephritis (LN) in an inflammation of the kidney caused by Systemic Lupus Erythematosus (SLE) and represents a serious
progression of SLE. SLE is a chronic, complex and often disabling disorder and affects more than 500,000 people in the United
States (mostly women). The disease is highly heterogeneous, affecting a wide range of organs & tissue systems. It is estimated
that as many as 60% of all SLE patients have clinical LN requiring treatment. Unlike SLE, LN has straightforward disease outcomes
where an early response correlates with long-term outcomes, measured by proteinuria. In patients with LN, renal damage results in
proteinuria and/or hematuria and a decrease in renal function as evidenced by reduced estimated glomerular filtration rate (eGFR),
and increased serum creatinine levels. LN is debilitating and costly and if poorly controlled, LN can lead to permanent and
irreversible tissue damage within the kidney, resulting in end-stage renal disease (ESRD), thus making LN a serious and potentially
life-threatening condition.
Investor & Media:
Celia Economides
Associate VP, Investor Relations
ceconomides@auriniapharma.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005293/en/